19 September 2018 - - US-based integrated design company Just Biotherapeutics, Inc and US-based biotechnology company Pandion Therapeutics, Inc. have entered into an agreement for the development and cGMP clinical manufacturing by Just of Pandion's lead programme, the company said.

Just will provide Pandion with a suite of services leveraging Just's fully integrated technology platform, J.DESIGN. The services include cell line development, process development, and Phase 1 cGMP clinical manufacturing of a selected drug candidate to expedite Pandion's IND filing by the end of 2019.

Just Biotherapeutics is a platform company that integrates the design, development and manufacture of biologics.

With experience in the fields of protein, process and manufacturing sciences, the Just team came together to solve the scientific and technical hurdles that block access to life-changing protein therapeutics, from the design of therapeutic molecules to the design of the manufacturing plants used to produce them.

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localised immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants.